First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer von Horn, Leora, Mansfield, Aaron S, Szczęsna, Aleksandra, Havel, Libor, Krzakowski, Maciej, Hochmair, Maximilian J, Huemer, Florian, Losonczy, György, Johnson, Melissa L, Nishio, Makoto, Reck, Martin, Mok, Tony, Lam, Sivuonthanh, Shames, David S, Liu, Juan, Ding, Beiying, Lopez-Chavez, Ariel, Kabbinavar, Fairooz, Lin, Wei, Sandler, Alan, Liu, Stephen V

Volltext

Intratumoral plasma cells predict outcomes to PD-L1 blockade in non-small cell lung cancer von Patil, Namrata S., Nabet, Barzin Y., Müller, Sören, Koeppen, Hartmut, Zou, Wei, Giltnane, Jennifer, Au-Yeung, Amelia, Srivats, Shyam, Cheng, Jason H., Takahashi, Chikara, de Almeida, Patricia E., Chitre, Avantika S., Grogan, Jane L., Rangell, Linda, Jayakar, Sangeeta, Peterson, Maureen, Hsia, Allison W., O’Gorman, William E., Ballinger, Marcus, Banchereau, Romain, Shames, David S.

Volltext

Results From the Phase III Randomized Trial of Onartuzumab Plus Erlotinib Versus Erlotinib in Previously Treated Stage IIIB or IV Non-Small-Cell Lung Cancer: METLung von Spigel, David R, Edelman, Martin J, O'Byrne, Kenneth, Paz-Ares, Luis, Mocci, Simonetta, Phan, See, Shames, David S, Smith, Dustin, Yu, Wei, Paton, Virginia E, Mok, Tony

Volltext

Recurrent Loss of NFE2L2 Exon 2 Is a Mechanism for Nrf2 Pathway Activation in Human Cancers von Goldstein, Leonard D., Lee, James, Gnad, Florian, Klijn, Christiaan, Schaub, Annalisa, Reeder, Jens, Daemen, Anneleen, Bakalarski, Corey E., Holcomb, Thomas, Shames, David S., Hartmaier, Ryan J., Chmielecki, Juliann, Seshagiri, Somasekar, Gentleman, Robert, Stokoe, David

Volltext

Metabolic Diversity in Human Non-Small Cell Lung Cancer Cells von Chen, Pei-Hsuan, Cai, Ling, Huffman, Kenneth, Yang, Chendong, Kim, Jiyeon, Faubert, Brandon, Boroughs, Lindsey, Ko, Bookyung, Sudderth, Jessica, McMillan, Elizabeth A., Girard, Luc, Chen, Dong, Peyton, Michael, Shields, Misty D., Yao, Bo, Shames, David S., Kim, Hyun Seok, Timmons, Brenda, Sekine, Ikuo, Britt, Rebecca, Weber, Stephanie, Byers, Lauren A., Heymach, John V., Chen, Jing, White, Michael A., Minna, John D., Xiao, Guanghua, DeBerardinis, Ralph J.

Volltext

Comprehensive genomic analysis identifies SOX2 as a frequently amplified gene in small-cell lung cancer von Rudin, Charles M, Durinck, Steffen, Stawiski, Eric W, Poirier, John T, Modrusan, Zora, Shames, David S, Bergbower, Emily A, Guan, Yinghui, Shin, James, Guillory, Joseph, Rivers, Celina Sanchez, Foo, Catherine K, Bhatt, Deepali, Stinson, Jeremy, Gnad, Florian, Haverty, Peter M, Gentleman, Robert, Chaudhuri, Subhra, Janakiraman, Vasantharajan, Jaiswal, Bijay S, Parikh, Chaitali, Yuan, Wenlin, Zhang, Zemin, Koeppen, Hartmut, Wu, Thomas D, Stern, Howard M, Yauch, Robert L, Huffman, Kenneth E, Paskulin, Diego D, Illei, Peter B, Varella-Garcia, Marileila, Gazdar, Adi F, de Sauvage, Frederic J, Bourgon, Richard, Minna, John D, Brock, Malcolm V, Seshagiri, Somasekar

Volltext

Neuregulin-1-Mediated Autocrine Signaling Underlies Sensitivity to HER2 Kinase Inhibitors in a Subset of Human Cancers von Wilson, Timothy R., Lee, Diana Y., Berry, Leanne, Shames, David S., Settleman, Jeff

Volltext

Analytical evaluation of circulating tumor DNA sequencing assays von Li, Wenjin, Huang, Xiayu, Patel, Rajesh, Schleifman, Erica, Fu, Shijing, Shames, David S., Zhang, Jingyu

Volltext

Oncogene mutations, copy number gains and mutant allele specific imbalance (MASI) frequently occur together in tumor cells von Soh, Junichi, Okumura, Naoki, Lockwood, William W, Yamamoto, Hiromasa, Shigematsu, Hisayuki, Zhang, Wei, Chari, Raj, Shames, David S, Tang, Ximing, MacAulay, Calum, Varella-Garcia, Marileila, Vooder, Tõnu, Wistuba, Ignacio I, Lam, Stephen, Brekken, Rolf, Toyooka, Shinichi, Minna, John D, Lam, Wan L, Gazdar, Adi F

Volltext

Emerging evidence of epithelial-to-mesenchymal transition in lung carcinogenesis von SATO, MITSUO, SHAMES, DAVID S., HASEGAWA, YOSHINORI

Volltext

The mutation spectrum revealed by paired genome sequences from a lung cancer patient von Lee, William, Jiang, Zhaoshi, Liu, Jinfeng, Haverty, Peter M., Guan, Yinghui, Stinson, Jeremy, Yue, Peng, Zhang, Yan, Pant, Krishna P., Bhatt, Deepali, Ha, Connie, Johnson, Stephanie, Kennemer, Michael I., Mohan, Sankar, Nazarenko, Igor, Watanabe, Colin, Sparks, Andrew B., Shames, David S., Gentleman, Robert, de Sauvage, Frederic J., Stern, Howard, Pandita, Ajay, Ballinger, Dennis G., Drmanac, Radoje, Modrusan, Zora, Seshagiri, Somasekar, Zhang, Zemin

Volltext

Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): an international, multicentre, single-arm, phase 2 trial von Rosell, Rafael, Prof, Dafni, Urania, Prof, Felip, Enriqueta, MD, Curioni-Fontecedro, Alessandra, MD, Gautschi, Oliver, MD, Peters, Solange, MD, Massutí, Bartomeu, MD, Palmero, Ramon, MD, Aix, Santiago Ponce, MD, Carcereny, Enric, MD, Früh, Martin, MD, Pless, Miklos, MD, Popat, Sanjay, FRCP, Kotsakis, Athanasios, MD, Cuffe, Sinead, MD, Bidoli, Paolo, MD, Favaretto, Adolfo, MD, Froesch, Patrizia, MD, Reguart, Noemí, MD, Puente, Javier, MD, Coate, Linda, MD, Barlesi, Fabrice, Prof, Rauch, Daniel, MD, Thomas, Michael, Prof, Camps, Carlos, MD, Gómez-Codina, Jose, MD, Majem, Margarita, MD, Porta, Rut, MD, Shah, Riyaz, FRCP, Hanrahan, Emer, MRCPI, Kammler, Roswitha, BA, Ruepp, Barbara, PharmD, Rabaglio, Manuela, MD, Kassapian, Marie, MSc, Karachaliou, Niki, MD, Tam, Rachel, BSc, Shames, David S, PhD, Molina-Vila, Miguel A, PhD, Stahel, Rolf A, Dr

Volltext

Human lung epithelial cells progressed to malignancy through specific oncogenic manipulations von Sato, Mitsuo, Larsen, Jill E, Lee, Woochang, Sun, Han, Shames, David S, Dalvi, Maithili P, Ramirez, Ruben D, Tang, Hao, DiMaio, John Michael, Gao, Boning, Xie, Yang, Wistuba, Ignacio I, Gazdar, Adi F, Shay, Jerry W, Minna, John D

Volltext

Both T cell priming in lymph node and CXCR3-dependent migration are the key events for predicting the response of atezolizumab von Iwai, Toshiki, Sugimoto, Masamichi, Patil, Namrata S., Bower, Daniel, Suzuki, Miho, Kato, Chie, Yorozu, Keigo, Kurasawa, Mitsue, Shames, David S., Kondoh, Osamu

Volltext

Genome and transcriptome sequencing of lung cancers reveal diverse mutational and splicing events von Liu, Jinfeng, Lee, William, Jiang, Zhaoshi, Chen, Zhongqiang, Jhunjhunwala, Suchit, Haverty, Peter M, Gnad, Florian, Guan, Yinghui, Gilbert, Houston N, Stinson, Jeremy, Klijn, Christiaan, Guillory, Joseph, Bhatt, Deepali, Vartanian, Steffan, Walter, Kimberly, Chan, Jocelyn, Holcomb, Thomas, Dijkgraaf, Peter, Johnson, Stephanie, Koeman, Julie, Minna, John D, Gazdar, Adi F, Stern, Howard M, Hoeflich, Klaus P, Wu, Thomas D, Settleman, Jeff, de Sauvage, Frederic J, Gentleman, Robert C, Neve, Richard M, Stokoe, David, Modrusan, Zora, Seshagiri, Somasekar, Shames, David S, Zhang, Zemin

Volltext

Blood First Assay Screening Trial (BFAST) in Treatment-Naive Advanced or Metastatic NSCLC: Initial Results of the Phase 2 ALK-Positive Cohort von Dziadziuszko, Rafal, Mok, Tony, Peters, Solange, Han, Ji-Youn, Alatorre-Alexander, Jorge, Leighl, Natasha, Sriuranpong, Virote, Pérol, Maurice, de Castro Junior, Gilberto, Nadal, Ernest, de Marinis, Filippo, Frontera, Osvaldo Arén, Tan, Daniel S.W., Lee, Dae Ho, Kim, Hye Ryun, Yan, Mark, Riehl, Todd, Schleifman, Erica, Paul, Sarah M., Mocci, Simonetta, Patel, Rajesh, Assaf, Zoe June, Shames, David S., Mathisen, Michael S., Gadgeel, Shirish M.

Volltext

A Translational View of the Molecular Pathogenesis of Lung Cancer von Sato, Mitsuo, Shames, David S., Gazdar, Adi F., Minna, John D.

Volltext

Clinical utility of a blood-based EGFR mutation test in patients receiving first-line erlotinib therapy in the ENSURE, FASTACT-2, and ASPIRATION studies von Wu, Yi-Long, Lee, Victor, Liam, Chong-Kin, Lu, Shun, Park, Keunchil, Srimuninnimit, Vichien, Wang, Jie, Zhou, Caicun, Appius, Anita, Button, Peter, Hooper, Gregory, Palma, John F., Schulze, Katja, Scudder, Sidney, Shames, David S., Yin, Anny-Yue, Zhang, Guili, Mok, Tony

Volltext

Knockdown of oncogenic KRAS in non-small cell lung cancers suppresses tumor growth and sensitizes tumor cells to targeted therapy von Sunaga, Noriaki, Shames, David S, Girard, Luc, Peyton, Michael, Larsen, Jill E, Imai, Hisao, Soh, Junichi, Sato, Mitsuo, Yanagitani, Noriko, Kaira, Kyoichi, Xie, Yang, Gazdar, Adi F, Mori, Masatomo, Minna, John D

Volltext

Safety and Pharmacokinetics/Pharmacodynamics of the First-in-Class Dual Action HER3/EGFR Antibody MEHD7945A in Locally Advanced or Metastatic Epithelial Tumors von Juric, Dejan, Dienstmann, Rodrigo, Cervantes, Andres, Hidalgo, Manuel, Messersmith, Wells, Blumenschein, Jr, George R, Tabernero, Josep, Roda, Desamparados, Calles, Antonio, Jimeno, Antonio, Wang, Xiaodong, Bohórquez, Sandra Sanabria, Leddy, Cecilia, Littman, Catherine, Kapp, Amy V, Shames, David S, Penuel, Elicia, Amler, Lukas C, Pirzkall, Andrea, Baselga, José

Volltext